The fight against rheumatism: From willow bark to COX-1 sparing drugs

Journal of Physiology and Pharmacology

Volumn 51, Issue 4, 2000, Pages 573-586

  Vane, J R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aspirin; COX 1; COX 2; NSAIDS; Prostaglandins; Rheumatism; Selective COX 2 inhibitor

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; PIROXICAM; PLANT EXTRACT; ROFECOXIB; SALICYLIC ACID DERIVATIVE;

ANTIPYRETIC ACTIVITY; ANTISEPSIS; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; PROSTAGLANDIN SYNTHESIS; RHEUMATIC DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ASPIRIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 0034527045     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (75)

1. An account of the success of the bark of the willow in the cure of agues
2. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
3. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs
4. Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data
5. Biosynthesis of prostaglandins from arachidonic acid in guinea pig lung. Prostaglandins and related factors. 38
6. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
7. Indomethacin and aspirin abolish prostaglandin release from spleen
8. Aspirin selectively inhibits prostaglandin production in human platelets
9. Inhibition of prostaglandin biosynthesis
10. Anti-inflammatory drugs and their mechanism of action
11. Cyclooxygenases 1 and 2
12. Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland
13. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-Acetamidophenol)
14. The role of copper in prostaglandin synthesis
15. Evidence for two distinct forms of fatty acid cyclooxygenase in brain
16. Examination of mouse and rat tissues for evidence of dual forms of the fatty acid cyclo-oxygenase
17. Evidence for two pools of prostaglandin H synthase in human endothelial cells
18. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation
19. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases
20. 2 synthase (cyclooxygenase) in human monocytes
21. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
22. Identification of a phorbol ester-repressible v-src-inducible gene
23. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
24. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
25. Multiple cyclooxygenases: Cloning of a mitogen-inducible form
26. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
27. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles
28. An enzyme isolated from arteries transforms prostaglandin endoperoxide to an unstable substance that inhibits platelet aggregation
29. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
30. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
31. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
32. Towards a better aspirin
33. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
34. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis
35. Safety of meloxicam: A global analysis of clinical trials
36. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model
37. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
38. Differential inhibition of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems
39. Selective inhibition of human cyclooxygenase-2 by meloxicam
40. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
41. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
42. Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (Lodine)
43. A randomised double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production
44. A review of selected newer nonsteroidal anti-inflammatory drugs
45. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs
46. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
47. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells
48. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
49. The macula densa: Recent developments
50. Cyclooxygenase-2 (COX-2) and the kidney: Current status and potential perspectives
51. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
52. Cyclooxygenase-2 is induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor
53. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus
54. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
55. -1-mice
56. The antipyretic action of acetaminophen: Inhibition of the cyclooxygenase activity of endothelial cells treated with IL-1
57. Antipyretic activity of a selective cyclooxygenase (COX-2) inhibitor, MK-0966
58. Use of a cyclo-oxygenase type-2 selective non-steroidal anti-inflammatory agent to prevent preterm delivery
59. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua
60. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4
61. Aspirin use and reduced risk of fatal colon cancer
62. Prevention of gastrointestinal cancer - The potential role of NSAIDs in colorectal cancer
63. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
64. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
65. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
66. □716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
67. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
68. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice
69. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
70. The Effect of celecoxib, a cyclo-oxygenase-2 inhibitor, in familial adenomatous polyposis
71. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
72. Neuroinflammatory mechanisms in Alzheimer's disease: New opportunities for drug discovery
73. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease
74. Risk of Alzheimer's disease and duration of NSAID use
75. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain